Lin Yangyi, Pang Lingpin, Huang Shian, Shen Jieyan, Wu Weifeng, Tang Fangming, Su Weiqing, Zhu Xiulong, Sun Jingzhi, Quan Ruilin, Yang Tao, Han Huijun, He Jianguo
Department of Pulmonary Vascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cardiovascular Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Front Cardiovasc Med. 2022 Aug 2;9:908215. doi: 10.3389/fcvm.2022.908215. eCollection 2022.
Pulmonary hypertension due to left heart failure (PH-LHF) is currently the most common form of pulmonary hypertension (PH) encountered in clinical practice. Despite significant advances that have improved our understanding of PH-LHF over the past two decades, the mortality is still high in recent decades. This study aimed to describe the prevalence and survival of patients with PH-LHF, and explored the potential risk factors which may predict the prognosis of PH-LHF.
A retrospective analysis of a prospective cohort study of left heart failure (LHF) patients who underwent right heart catheterization (RHC) between January 2013 and November 2016 was performed. The endpoint was all-cause mortality. Follow-ups were performed every 6 months ± 2 weeks.
A total of 480 patients with LHF were enrolled, with 215 (44.8%) having PH-LHF. The proportion of PH-LHF was significantly lower in coronary artery disease (CAD) group than without CAD (41.3 vs. 57.8%, = 0.003). However, multivariable logistic regression analysis revealed that CAD was not associated with PH-LHF (Adjusted OR: 1.055, 95% CI: 0.576 - 1.935, = 0.862). 75 of 215 (34.9%) patients with PH-LHF died during a median follow-up period of 84.6 months. The 1-, 3-, 5-, and 8-year survival rates of all PH-LHF patients were 94.3, 76.9, 65.8, and 60.2%, respectively. New York Heart Association Functional Class (NYHA FC), hemoglobin, and systolic pulmonary artery pressure (sPAP) were associated with mortality of PH-LHF in multivariate Cox analysis.
PH is commonly identified in patients with LHF, with a prevalence of approximately 45%. The mortality is still high in patients with PH-LHF. NYHA FC, hemoglobin, and sPAP are independent risk predictors of mortality for PH-LHF. These findings may be useful for risk stratification in future clinical trial enrollment.
左心衰竭所致肺动脉高压(PH-LHF)是目前临床实践中最常见的肺动脉高压(PH)类型。尽管在过去二十年里我们对PH-LHF的认识有了显著进展,但近几十年来其死亡率仍然很高。本研究旨在描述PH-LHF患者的患病率和生存率,并探索可能预测PH-LHF预后的潜在危险因素。
对2013年1月至2016年11月期间接受右心导管检查(RHC)的左心衰竭(LHF)患者的前瞻性队列研究进行回顾性分析。终点为全因死亡率。每6个月±2周进行一次随访。
共纳入480例LHF患者,其中215例(44.8%)患有PH-LHF。冠心病(CAD)组中PH-LHF的比例显著低于无CAD组(41.3%对57.8%;P = 0.003)。然而,多变量逻辑回归分析显示CAD与PH-LHF无关(调整后的比值比:1.055,95%可信区间:0.576 - 1.935;P = 0.862)。215例PH-LHF患者中有75例(34.9%)在中位随访期84.6个月内死亡。所有PH-LHF患者的1年、3年、5年和8年生存率分别为94.3%、76.9%、65.8%和60.2%。多变量Cox分析显示,纽约心脏协会心功能分级(NYHA FC)、血红蛋白和收缩期肺动脉压(sPAP)与PH-LHF的死亡率相关。
LHF患者中常见PH,患病率约为45%。PH-LHF患者的死亡率仍然很高。NYHA FC、血红蛋白和sPAP是PH-LHF死亡率的独立风险预测因素。这些发现可能有助于未来临床试验入组时的风险分层。